Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Polatuzumab

Home DrugsPolatuzumab

Polatuzumab

Unknown Manufacturer

Generate AI report

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

METHODS FOR TREATMENT OF CD20-POSITIVE PROLIFERATIVE DISORDER WITH MOSUNETUZUMAB AND POLATUZUMAB VEDOTIN
EP 4337330 A1Applicant: GENENTECH INCPriority: 2021
EP
US
WO
7 publications
COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ANTI-SIRPALPHA ANTIBODY
EP 4523702 A4Applicant: DAIICHI SANKYO CO LTDPriority: 2022
EP
US
WO
3 publications
MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA
EP 4724813 A1Applicant: GENENTECH INCPriority: 2023
EP
US
WO
3 publications
METHODS FOR TREATING CANCER USING SUBCUTANEOUS DOSING OF MOSUNETUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN
US 20260078198 A1Applicant: GENENTECH INCPriority: 2024
US
WO
2 publications
BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA
US 20250101102 A1Applicant: GENMAB ASPriority: 2023
US